H. Lee Moffitt Cancer Center and Research Institute, Inc.

University of South Florida

The United States Government As Represented by the Department of Veterans Affairs

Forma Therapeutics, Inc.

Pearlie Burnette

Nicholas James Lawrence

Harshani Lawrence

David R Lancia, Jr

Xiaozhang Zheng

Pui Yee Ng

Bingsong Han

Matthew W Martin

Cuixian Liu

Aleksandra Rudnitskaya

Jennifer R Thomason

Nicholas Barczak

Srikumar Chellappan

Jennifer Lee

Jaime A Escobedo

Chiara Conti

Jessica M McDaniel

Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.

Dimeric immuno-modulatory compounds against cereblon-based mechanisms

Small molecules against cereblon to enhance effector t cell function

The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

Methods using HDAC11 inhibitors

Disclosed are compositions and methods for predicting responsiveness of a subject to treatment with lenalidomide (LEN) by assaying a sample from the subject for surface expression of CD28 on T-cells. Also provided is a method of treating a subject for cancer that involves assaying a sample from the subject for surface expression of CD28 on T-cells and then treating them with LEN if they do not have reduced CD28 surface expression on the T-cells. Also provided is a method for promoting responsiveness of a subject to LEN by administering to the subject a composition that promotes expression of CD28 on the surface of T-cells.

CD28 expression during lenalidomide immune modulation

The subject invention concerns methods and materials for assessing a patient's likelihood of responsiveness to an immunosuppressive therapy. The subject invention is contemplated for use with patients having an autoimmune disorder. In an exemplified embodiment, the methods of the invention are used for assessing and/or treating a patient with MDS. In one embodiment, a method of the invention comprises analyzing T cells of a patient for dysregulation of CD4and/or CD8T cell subsets, and determining the patient's likelihood of responsiveness to IST based on the level of dysregulation of the patient's CD4and/or CD8T cell subsets. In one embodiment, an increased likelihood of patient responsiveness to IST is associated with an increased percentage of CD4and/or CD8effector memory T cells and/or terminal effector memory T cells for a patient. The subject invention also concerns methods for treating a patient with an autoimmune disorder, such as MDS. In one embodiment, a method of the invention comprises determining if a patient is likely to respond to IST, wherein said determination is made using a method of the present invention for assessing likelihood of responsiveness to IST; and if the patient is determined to be one likely to respond to IST, administering an effective regimen of IST to the patient.

Biomarkers for predicting response to immunosuppressive therapy

Growing community of inventors

Tampa, FL, United States of America

Pearlie Burnette